Wockhardt Share Price Today | Stock Price & Wockhardt Share Screener
As of November 18, 2026, the live Wockhardt share price (NSE: WOCKPHARMA) is ₹2,026.60 on NSE and ₹2,027.10 on BSE, up 0.88% from the previous close, with shares trading between ₹2,005.00 and ₹2,065.00 in today's trading session, and a 52-week range of ₹1,100.30–₹2,329.70. Track Wockhardt marketcap in USD to gauge the company's total market size. Use the Wockhardt stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Wockhardt opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹980 and net income of ₹73, with EBITDA of ₹184, an operating margin of 18.0% and a profit margin of 7.5%.
Wockhardt Share Price Chart
Track the current stock price of Wockhardt with an interactive chart. Analyse WOCKPHARMA share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Wockhardt stock quote in one place.
The quote of ₹2,026.60 sits between the 52-week low of ₹1,100.30 and the 52-week high of ₹2,329.70, and the latest session moved 0.88% from the previous close.
Wockhardt Company Profile - Fundamental Screener
Screen Wockhardt company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for WOCKPHARMA shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE049B01025.
Company Details
Classification
Identifiers and Leadership
Wockhardt Balance Sheet Screener
Screen WOCKPHARMA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹8,615, up from ₹8,135 in 2025.
Latest statistics put total assets at ₹8,615 and shareholder funds at ₹5,281, with a leverage ratio of 0.46.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 8,615 | 8,135 | 7,649 | 7,683 | 8,243 | 7,774 | 8,179 | 7,844 | 8,162 | 9,022 |
| Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Assets | 2,791 | 2,736 | 2,881 | 3,042 | 3,462 | 3,343 | 3,502 | 3,058 | 2,888 | 2,773 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 1,712 | 1,436 | 1,196 | 586 | 834 | 894 | 1,624 | 1,976 | 2,272 | 3,324 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 5,281 | 4,657 | 3,662 | 3,662 | 4,202 | 3,759 | 3,058 | 3,005 | 3,198 | 3,719 |
| Share Capital | 81 | 81 | 77 | 72 | 72 | 55 | 55 | 55 | 55 | 55 |
| Reserves & Surplus | 4,859 | 4,272 | 3,282 | 3,282 | 3,777 | 3,321 | 2,616 | 2,620 | 2,797 | 3,281 |
Wockhardt Income Statement Screener - Profit & Revenue Analysis
Screen Wockhardt income statement and profit fundamentals. Analyze WOCKPHARMA quarterly results. Wockhardt reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Sept, revenue was ₹980 and net profit was ₹73, equal to earnings per unit of ₹4.85, at an operating margin of 18%.
In that period expenses were ₹796, interest cost ₹56 and tax ₹0. The next period listed, 2026-Jun, shows revenue of ₹960 and net profit of ₹107.
| Item | 2026-Sept | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||||
| Revenue | 980 | 960 | 1,032 | 913 | 803 | 758 | 758 | 729 | 818 | 769 | 754 | 709 | 777 | 658 | 710 |
| Expenses | 796 | 737 | 740 | 721 | 604 | 763 | 679 | 593 | 699 | 648 | 803 | 664 | 681 | 642 | 771 |
Operating Costs and Margins | |||||||||||||||
| EBITDA | 184 | 223 | 292 | 192 | 199 | -5 | 79 | 136 | 119 | 121 | -49 | 45 | 96 | 16 | -61 |
| Operating Profit % | 18.00% | 21.00% | 23.00% | 19.00% | 23.00% | -3.00% | 9.00% | 18.00% | 14.00% | 12.00% | -15.00% | 5.00% | 10.00% | 0.00% | -14.00% |
| Depreciation | 55 | 55 | 53 | 65 | 53 | 56 | 53 | 55 | 55 | 54 | 58 | 55 | 55 | 55 | 56 |
| Interest | 56 | 52 | 50 | 60 | 55 | 48 | 48 | 60 | 73 | 73 | 73 | 77 | 76 | 79 | 76 |
Profit and Earnings | |||||||||||||||
| Profit Before Tax | 73 | 116 | 189 | 67 | 91 | -109 | -22 | 21 | -9 | -6 | -180 | -87 | -35 | -118 | -193 |
| Tax | 0 | 9 | 25 | 6 | 9 | -1 | 23 | 1 | 7 | 10 | -3 | -1 | 38 | 18 | 44 |
| Net Profit | 73 | 107 | 164 | 61 | 82 | -108 | -45 | 20 | -16 | -16 | -177 | -86 | -73 | -136 | -237 |
| EPS | 4.85 | 6.55 | 10.23 | 3.61 | 4.81 | -5.53 | -1.57 | 0.91 | -1.47 | -0.95 | -11.64 | -5.75 | -5.37 | -9.28 | -14.37 |
Wockhardt Cash Flow Screener - Liquidity Fundamentals
Screen WOCKPHARMA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹390, and net cash flow was an inflow of ₹105.
Over the same period, investing activities used ₹231 and financing activities used ₹54.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | 390 | -22 | 219 | 153 | 413 | -287 | 649 | 183 | 68 | -270 |
| Investing Activities | -231 | -780 | -138 | -118 | -204 | 1,471 | -147 | 93 | 635 | -684 |
Financing and Net Cash | ||||||||||
| Financing Activities | -54 | 409 | 334 | -315 | -71 | -1,171 | -680 | -777 | -770 | 1,255 |
| Net Cash Flow | 105 | -393 | 415 | -280 | 138 | 13 | -178 | -500 | -66 | 301 |
Wockhardt Shareholding Pattern Screener
See Wockhardt shareholding pattern with promoter, FII, and DII holdings. Check Wockhardt promoter holding and ownership changes for WOCKPHARMA on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Sept, promoters held 49.33%, foreign institutions 7.02%, domestic institutions 9.00% and the public 26.90%, spread across 173,116 shareholders.
The shareholder count was 173,116 in 2026-Sept, compared with 166,518 in 2026-Jun.
| Item | 2026-Sept | 2026-Jun | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 49.33% | 49.08% | 49.08% | 49.09% | 49.09% | 49.08% | 49.08% | 51.60% |
Institutional Investors | ||||||||
| FII Holding | 7.02% | 7.22% | 7.09% | 6.81% | 7.29% | 7.10% | 6.99% | 5.49% |
| DII Holding | 9.00% | 9.24% | 10.96% | 10.59% | 11.01% | 11.01% | 10.55% | 4.83% |
Government, Public and Others | ||||||||
| Govt Holding | 0.01% | 0.02% | 0.04% | 0.02% | 0.02% | 0.02% | 0.02% | 0.01% |
| Public Holding | 26.90% | 27.31% | 25.89% | 26.69% | 26.05% | 26.10% | 26.52% | 29.94% |
| Other Holding | 7.74% | 7.13% | 6.94% | 6.80% | 6.55% | 6.69% | 6.84% | 8.13% |
| Shareholder Count | 173,116 | 166,518 | 139,016 | 141,799 | 146,918 | 137,946 | 142,274 | 146,376 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Wockhardt. Wockhardt dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹0.00 per unit for 2026-March, a yield of 0.00%, compared with ₹0.00 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹0.00, ₹0.00 and ₹0.00 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.00 | 0.00% |
| 2024-March | ₹0.00 | 0.00% |
| 2023-March | ₹0.00 | 0.00% |
| 2022-March | ₹0.00 | 0.00% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹10.00 | 1.49% |
Wockhardt Stock Index Membership - Nifty & Sensex
See which indices include Wockhardt stock. Check WOCKPHARMA index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
The company is listed in 9 indices, including BSE 1000.
Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX SMLCAP, NIFTY 500.
Complete Index List
Wockhardt Market Events Screener - Corporate Actions
Get Wockhardt corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Wockhardt stock events that may affect WOCKPHARMA share price, along with derivatives, futures and options activity and sector gainers.
13 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 2, 2026, with a record date of November 2, 2026.
It is followed by Quarterly Result Announcement dated August 10, 2026 and Annual General Meeting dated August 10, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-11-02 | 2026-11-02 | Quarterly Result Announcement | NA | 5.06% |
| 2026-08-10 | 2026-08-10 | Quarterly Result Announcement | NA | -0.31% |
| 2026-08-10 | 2026-08-10 | Annual General Meeting | NA | 3.71% |
| 2026-05-04 | 2026-05-04 | Quarterly Result Announcement | NA | -2.98% |
| 2026-02-10 | 2026-02-10 | Quarterly Result Announcement | NA | 4.53% |
| 2025-11-03 | 2025-11-03 | Quarterly Result Announcement | NA | -1.11% |
| 2025-08-08 | 2025-08-08 | Quarterly Result Announcement | NA | -8.90% |
| 2025-08-08 | 2025-08-08 | Annual General Meeting | NA | -16.90% |
| 2025-05-29 | 2025-05-29 | Quarterly Result Announcement | NA | 1.28% |
| 2025-02-07 | 2025-02-07 | Quarterly Result Announcement | NA | 5.94% |
| 2024-11-13 | 2024-11-13 | Quarterly Result Announcement | NA | -2.13% |
| 2024-06-28 | 2024-06-28 | Annual General Meeting | NA | 26.97% |
| 2022-03-08 | 2022-03-09 | Rights | 3:10 | -1.13% |
Wockhardt Competitors Screener - Peer Stocks Comparison
Screen WOCKPHARMA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 448,076 | 41.10 | 61,674 | 12.69% | 11,565 | 59.98 |
| Divis Laboratories | 294,139 | 90.70 | 11,067 | 13.95% | 2,568 | 67.88 |
| Torrent Pharmaceuticals | 178,438 | 84.50 | 13,886 | 20.34% | 2,138 | 49.31 |
| Laurus Labs | 119,949 | 98.10 | 6,868 | 22.01% | 890 | 49.19 |
| Zydus Life Science | 118,902 | 27.60 | 27,658 | 17.64% | 5,026 | 52.87 |
| Dr Reddys Laboratories | 115,011 | 41.70 | 35,059 | 3.90% | 4,158 | 69.34 |
| Cipla | 112,656 | 39.40 | 29,045 | 2.24% | 3,870 | 55.82 |
| Mankind Pharma | 108,490 | 48.40 | 14,636 | 14.85% | 1,938 | 63.62 |
| Aurobindo Pharma | 103,223 | 26.40 | 34,145 | 5.56% | 3,503 | 60.38 |
| Lupin | 90,393 | 17.30 | 29,039 | 26.75% | 5,356 | 44.23 |
Wockhardt Company Announcements - News & Reports Screener
Screen WOCKPHARMA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated November 12, 2026.
The next most recent announcements are dated November 2, 2026 and November 2, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-11-12 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-11-02 | Announcement under Regulation 30 (LODR)-Monitoring Agency Report | - |
| 2026-11-02 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-11-02 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-11-02 | Quarter And Half Year Ended September 30 2026. | - |
| 2026-11-02 | Board Meeting Outcome for Financial Result For The Quarter And Half Year Ended September 30 2026 | - |
| 2026-10-27 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | - |
| 2026-10-27 | Board Meeting Intimation for Intimation Of The Meeting Of Board Of Directors Of Wockhardt Limited (The Company) | - |
| 2026-10-24 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-10-09 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-09-25 | Closure of Trading Window | - |
| 2026-08-25 | Disclosure under Regulation 30A of LODR | - |
| 2026-08-25 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-10 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-08-10 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-08-10 | Announcement under Regulation 30 (LODR)-Monitoring Agency Report | - |
| 2026-08-10 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-08-10 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-08-10 | Financial Results For The Quarter Ended 30Th June 2026 | - |
| 2026-08-10 | Board Meeting Outcome for Outcome Of The Board Meeting | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹2,026.60, within a 52-week range of ₹1,100.30 to ₹2,329.70. The P/E ratio is 81.50 and the P/B ratio is 6.40, with earnings per unit of ₹13.12. Market capitalisation stands at ₹32,571.56 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 19, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.